Compare Cassava Sciences Inc (FLNA) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Tango Therapeutics Inc. — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is far larger — about 104.4× Cassava Sciences Inc's market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and Tango Therapeutics Inc. for 0 Days on average.
| FLNA | TNGX | |
|---|---|---|
Market Cap | $35.91M | $3.75B |
Volume | 323,246 | 9,619,106 |
Sector | Health | Health |
52-Week High | $4.64 | $32.90 |
52-Week Low | $0.68 | $7.50 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$46.77M | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7316, down 4.93% today, amid bearish technical signals despite recent FDA progress. The stock shows negative profitability with ROE at -55.79% and consistent negative cash flow, though it has beaten EPS estimates for three consecutive quarters. Analyst consensus remains positive with 8 buy ratings versus 4 holds.
The outlook hinges on clinical development success, particularly the Phase 2a study for TSC-related epilepsy. Investment opportunity exists if trials progress favorably, but risks include cash burn, regulatory hurdles, and persistent losses. Current valuation metrics like EV/EBITDA of 1.11 suggest potential upside if execution improves.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
